Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

0.9999 -0.0001 (-0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200
Open 0.9999
Bid (Size) 0.9588 (1)
Ask (Size) 1.050 (40)
Prev. Close 1.000
Today's Range 0.9999 - 0.9999
52wk Range 0.9400 - 9.540
Shares Outstanding 46,553,511
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
Recap: Corvus Pharmaceuticals Q4 Earnings
Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga

Performance

YTD
-59.68%
-59.68%
1 Month
-25.93%
-25.93%
3 Month
-43.51%
-43.51%
6 Month
-70.42%
-70.42%
1 Year
-61.09%
-61.09%

More News

Read More
Earnings Scheduled For March 10, 2022
Via Benzinga
A Preview Of Corvus Pharmaceuticals's Earnings
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Via Benzinga
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Week In Review: Fosun Pharma Acquires Majority Stake In China Vaccine Company For $682 Million
Via Talk Markets
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
51 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
Via FinancialNewsMedia
Exposures COVID-19
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
20 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Why Corvus Pharmaceuticals Stock Is Down Today
Via The Motley Fool
Exposures COVID-19
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
Via FinancialNewsMedia
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.